Aragen expects to ride wave of US biotech growth in 2022

4 November 2021

India-based Aragen Life Sciences (formerly, GVK BIO), which offers R&D and manufacturing solutions (CRO/CDMO) for life sciences industries worldwide, expects high teens growth in 2022, with the new chemical entity (NCE) development and manufacturing business growing at around 40% year-on-year.

The company states growth is being predominantly driven by biotech partners with innovative products, particularly those in the USA, where outsourcing demand is growing quickly.

Consequently, the company expects to add around 400 scientists over the next year – taking the total scientists employed to 3,200 – with the company’s cell line development services also expanding extremely quickly (mid-teens) and plans are already underway for a USA-based biologics manufacturing facility (most likely through acquisition).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK